NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Guideline Alliance (UK). Cystic Fibrosis: Diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)
D.1. Diagnosis of cystic fibrosis
Download PDF (292K)
D.2. Information and support
Download PDF (292K)
D.3. Service configuration
Download PDF (284K)
D.4. Multidisciplinary teams
Download PDF (261K)
D.5. Transition from paediatric to adult services
Download PDF (256K)
D.6. Complications of cystic fibrosis
Download PDF (247K)
D.7. Monitoring for pulmonary disease onset in people with CF without clinical signs or symptoms of lung disease
Download PDF (353K)
D.8. Monitoring for evolving pulmonary disease in people with CF with established lung disease
Download PDF (306K)
D.9. Monitoring for pulmonary disease
Download PDF (357K)
D.10. Airway clearance techniques
Download PDF (308K)
D.11. Mucoactive agents
Download PDF (296K)
D.12. Pulmonary Infection prophylaxis
Download PDF (312K)
D.13. Pulmonary Infection - Antimicrobials for the treatment of acute pulmonary infection or those with an exacerbation
Download PDF (433K)
D.14. Pulmonary Infection - Antimicrobial agents for chronic pulmonary infection
Download PDF (393K)
D.15. Immunomodulatory agents
Download PDF (290K)
D.16. Nutritional interventions
Download PDF (278K)
D.17. Exocrine pancreatic insufficiency
Download PDF (284K)
D.18. Treatment and secondary prevention for distal intestinal obstruction syndrome
Download PDF (303K)
D.19. Monitoring for liver disease
Download PDF (312K)
D.20. Ursodeoxycholic acid for cystic fibrosis-related liver disease
Download PDF (294K)
D.21. Monitoring for CFRD
Download PDF (284K)
D.22. Monitoring for low BMD
Download PDF (274K)
D.23. Exercise
Download PDF (286K)
D.24. Psychological assessment
Download PDF (297K)
D.25. Cross infection control
Download PDF (300K)
- Diagnosis of cystic fibrosis
- Information and support
- Service configuration
- Multidisciplinary teams
- Transition from paediatric to adult services
- Complications of cystic fibrosis
- Monitoring for pulmonary disease onset in people with CF without clinical signs or symptoms of lung disease
- Monitoring for evolving pulmonary disease in people with CF with established lung disease
- Monitoring for pulmonary disease
- Airway clearance techniques
- Mucoactive agents
- Pulmonary Infection prophylaxis
- Pulmonary Infection - Antimicrobials for the treatment of acute pulmonary infection or those with an exacerbation
- Pulmonary Infection - Antimicrobial agents for chronic pulmonary infection
- Immunomodulatory agents
- Nutritional interventions
- Exocrine pancreatic insufficiency
- Treatment and secondary prevention for distal intestinal obstruction syndrome
- Monitoring for liver disease
- Ursodeoxycholic acid for cystic fibrosis-related liver disease
- Monitoring for CFRD
- Monitoring for low BMD
- Exercise
- Psychological assessment
- Cross infection control
- Review protocols - Cystic FibrosisReview protocols - Cystic Fibrosis
- Sebacina cf. vermifera sensu Warcup & Talbot strain Warcup 963 28S large subunit...Sebacina cf. vermifera sensu Warcup & Talbot strain Warcup 963 28S large subunit ribosomal RNA gene, partial sequencegi|46095005|gb|AY505554.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...